Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nexalin Technology Inc (NXL)

Nexalin Technology Inc (NXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,604
  • Shares Outstanding, K 18,652
  • Annual Sales, $ 170 K
  • Annual Income, $ -7,610 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 3.95
  • Price/Sales 48.00
  • Price/Cash Flow N/A
  • Price/Book 2.29
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.66
  • Most Recent Earnings $-0.13 on 11/14/25
  • Next Earnings Date 03/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Business Services
  • INDUSTRY GROUPING Technology Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +2.98%
on 02/06/26
0.8000 -35.64%
on 01/08/26
-0.2475 (-32.46%)
since 01/06/26
3-Month
0.5000 +2.98%
on 02/06/26
1.3600 -62.14%
on 11/10/25
-0.7351 (-58.81%)
since 11/06/25
52-Week
0.5000 +2.98%
on 02/06/26
3.8000 -86.45%
on 02/07/25
-3.1651 (-86.01%)
since 02/06/25

Most Recent Stories

More News
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Receives Nasdaq Listing Status Notification

HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

HOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.5149 (-16.95%)
NXLIW : 0.0138 (-9.21%)

Business Summary

Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.

See More

Key Turning Points

3rd Resistance Point 0.8099
2nd Resistance Point 0.7450
1st Resistance Point 0.6299
Last Price 0.5149
1st Support Level 0.4499
2nd Support Level 0.3850
3rd Support Level 0.2699

See More

52-Week High 3.8000
Fibonacci 61.8% 2.5394
Fibonacci 50% 2.1500
Fibonacci 38.2% 1.7606
Last Price 0.5149
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar